News coverage about Chembio Diagnostics (NASDAQ:CEMI) has trended somewhat positive on Saturday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Chembio Diagnostics earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.2388618618077 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Separately, ValuEngine upgraded shares of Chembio Diagnostics from a “strong sell” rating to a “sell” rating in a report on Friday, August 11th.

Chembio Diagnostics (NASDAQ CEMI) opened at $6.85 on Friday. The company has a current ratio of 3.54, a quick ratio of 2.19 and a debt-to-equity ratio of 0.01. Chembio Diagnostics has a twelve month low of $5.05 and a twelve month high of $7.05.

TRADEMARK VIOLATION WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/chembio-diagnostics-cemi-given-media-impact-rating-of-0-24/1725758.html.

Chembio Diagnostics Company Profile

Chembio Diagnostics, Inc (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc, develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company’s products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies.

Insider Buying and Selling by Quarter for Chembio Diagnostics (NASDAQ:CEMI)

Receive News & Ratings for Chembio Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.